This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says
- Posted on April 17, 2026
- By CNBC
- 0 Views
This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says
Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according to Goldman Sachs.
